Human medicines European public assessment report (EPAR): Abraxane, paclitaxel, Date of authorisation: 11/01/2008, ...
In metastatic breast cancer, Abraxane was more effective than conventional paclitaxel-containing medicines. Overall, in the main study, 31% of the women receiving Abraxane responded to treatment (72 out of 229), compared with 16% of the women receiving …